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Abstract 
Background: Methamphetamine (MA) which is known as “shisheh” in Iran is a drug that widely is used in 
many parts of the world and it is near to a decade that is available for the most drug users and has a 
considerable prevalence of use. Due to high abuse prevalence and very new challenging phenomenon, it is 
very important that researchers and treatment providers become more familiar with different aspects of MA. 
Discussion: It has multiple neurobiological impacts on the nervous system, some of which are transitory and 
some longer lasting. MA activates the reward system of the brain and produces effects that are highly 
reinforcing, which can lead to abuse and dependence. Routes of administration that produce rapid onset of 
the drug’s effects (i.e., smoking and injection) are likely to lead to more rapid addiction and more medical 
and psychiatric effects. No effective pharmacotherapies have been developed for the treatment of MA 
dependence; although, this is an area of very active research. Several behavioral treatments have been shown 
to reduce MA use, but better treatments are needed. 
Conclusion: Harm reduction strategies for non-treatment seeking MA users are needed to reduce the risk of 
human immunodeficiency virus and other medical risks. The research agenda for MA is substantial, with 
development of effective pharmacotherapies as one of the most important priorities. Appropriate and 
effective response for prevention, treatment and harm reduction services due to increasing problems 
regarding MA in Iran and some other countries in the region. 
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Introduction 
Worldwide, as many as 52 million individuals 
aged 15-64 are estimated to have used 
amphetamine-type stimulants for non-medical 
purposes at least once in the past year. 
Methamphetamine (MA) is the second most 
widely abused illicit drug in the world (following 
cannabis); its users nearly outnumber heroin and 
cocaine users combined. About two-thirds of the 
world’s MA/amphetamine users reside in East 
and Southeast Asia, followed by approximately 
one-fifth in the Americas (specifically the United 
States and Northern Mexico). 
Iran has a special situation in Asia and Middle 
East, with regard to amphetamine type stimulants 
(ATS) availability and use. Prior to 2004, there 
were no reported seizures of ATS in Iran. The first 
reported of ATS seizure was in 2005,1 followed by 
an increasing number of seizures, year by year.2-7 
The amount of MA seized qualified Iran for 
ranking 5th in ATS seizures in 2010 and 2011.6,7 
There was a 400% increase in the amount of ATS 
seized in Iran between 2010 and 2011, this 1 year 
rate of increase compares to increases of 238% in 
Mexico 166% in Thailand, 153% in USA and 140% 
in China, put Iran in 1st ranking for an increase in 
seizure. 
Discussion 
Pharmacology of MA 
MA increases activation of the dopamine, 
norepinephrine, and serotonin systems. MA use 
causes the release of dopamine into the synaptic 
cleft, increasing dopamine concentration. 
Furthermore, MA inhibits transport of dopamine 
into the storage vesicles, thus increasing the 
synaptic dopamine concentration. This 
abnormally high concentration of dopamine 
contributes to the severe neurotoxicity of MA. 
Heavy daily MA use and high dosages over a 
long duration result in neurobiological deficits 
that do not resolve until many months following 
cessation of use.8–10 
Besides the acute dopaminergic stimulation, 
MA produces norepinephrine effects such as mild 
elevation of pulse and blood pressure and 
cutaneous vasoconstriction, but it is important to 
know that some chronic users shows a 
unpredictable hypotension during general 
anesthesia in operation rooms, which one of the 
possible cause is down-regulation of endogenous 
catecholamine receptors.11 
Higher doses increase central nervous system 
stimulation, manifested as increased alertness and 
compulsive or repetitive behavior. MA users have 
increased sympathomimetic effects such as 
dizziness, tremor, hyperreflexia, pyrexia, 
mydriasis, diaphoresis, tachypnea, tachycardia, 
and hypertension.12 The drug has a prolonged  
half-life (10-12 h) and long duration of action. 
Elevated levels of dopamine in the central nervous 
system are associated with the reinforcing and 
highly addictive properties of MA. 
Route of administration 
MA can be used orally or intranasal, or it can be 
smoked or injected intravenously. Injection and 
smoked administration of MA carry higher risk 
for acute toxicity as well as greater potential for 
the development of addiction. In general, the 
rapid onset of euphoria provided by these routes 
of administration provides a powerful stimulus 
for re-administration of the drug to maintain the 
euphoria. When injected intravenously, MA 
reaches cerebral circulation in 10-15 s. When 
smoked, it reaches the brain in 6-8 s; smoking can 
achieve blood levels comparable to those reached 
through intravenous injection.13,14 These routes 
also have the most potential for toxicity due to 
rapid dose escalation. Intranasal insufflation 
(snorting) of MA produces euphoria in 3-5 min.14 
Absorption of orally administered MA occurs 
more slowly from the intestines, with peak 
plasma levels being reached 180 min after 
dosing.15 Clinical reports recount dependence-
level users taking 50 to 1000 mg of MA daily. 
MA injection in Iran is reporting recently in 
different cities with high rate of injection and 
shared injection both in closed and open setting, 
which is an alarming sign for human 
immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) prevention 
programs in Iran.16–18 
Symptoms of MA use, misuse, and dependence 
MA use increases blood pressure, body 
temperature, heart rate, and breathing rate. 
Continued use is common because of rewarding 
effects such as euphoria, reduced fatigue, reduced 
hunger, increased energy, increased sex drive, 
and increased self-confidence. Negative acute 
effects include abdominal cramps, shaking, high 
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body temperature, bruxism (teeth grinding), 
stroke, and cardiac arrhythmia, as well as 
increased anxiety, insomnia, aggressive 
tendencies, paranoia, and hallucinations. 
The acute subjective effects of MA use depend 
on the amount used and route of administration. 
The effects of injection and smoking are rapid and 
intense, often described as a “rush,” followed by 
euphoria and a sense of increased energy, 
wakefulness, alertness, and increased libido. 
Heart rate, blood pressure, and breathing rate 
increase and many users will grind their teeth and 
pick at their skin. Effects of MA can last up to 12 
h. Due to the development of tolerance, chronic 
MA users repeat dosing every few hours in 
“binging” episodes, which can result in paranoia, 
hallucinations, delusions, mood disturbance, and 
formication (tactile hallucination of bugs crawling 
on the skin). 
After prolonged or heavy use of MA, a 
withdrawal syndrome may emerge characterized 
by dysphoric mood, anhedonia, fatigue, increased 
appetite, sleep disturbance, and slowing, or 
acceleration of psychomotor activity.19 The 
severity of withdrawal is related to the duration 
and intensity of recent MA use.20 MA-dependent 
individuals have reported remission of the most 
severe withdrawal symptoms within several days 
to 3 weeks; although, there have been numerous 
clinical observations of more subtle symptoms 
(i.e., anhedonia) lasting for several months.21,22 
Apathy has been reported more frequently than 
depressed mood, suggesting that anhedonia may 
be more problematic than major depressive 
disorder following cessation of MA use.23 
Psychiatric considerations 
MA-associated psychiatric impairment may occur 
in several domains: cognitive, intellectual, or 
affective. The drug’s contribution to impairment 
may be acute, delayed, or cumulative/residual. 
Psychiatric impairment appears to correlate with 
duration of use as well as total and peak amounts 
of MA absorbed. Neurocognitive deficits 
associated with chronic MA use include 
impairments in episodic memory, executive 
functions, and psychomotor tasks related to 
frontostriatal and limbic circuits. MA use may 
also be associated with deficits in attention, 
memory, and language.24 Neurocognitive 
impairment may persist for 9 months or longer 
following cessation of MA use, but recovery in 
DAT activity and improvement in cognitive 
functioning is possible with sustained 
abstinence.25–27 
Psychiatric symptoms have been well-
documented in MA users.27 Anxiety, depression, 
insomnia, and psychosis are among the most 
commonly reported symptoms associated with 
MA dependence, and individuals presenting to 
the emergency department in the context of MA 
intoxication may be agitated, violent, or 
suicidal.28,29 Though minor agitation may be 
treated by placing the individual in a quiet, less 
stimulating environment, benzodiazepines, or 
neuroleptics may be required for more severe 
MA-related agitation or psychosis.29 
Psychiatric symptoms may vary as a result of 
individual differences in sensitivity to MA, 
amount and/or frequency of use, and route of 
administration.30 Individuals who use 
intravenously and who have a family history of 
psychotic symptoms are at heightened risk for the 
development of MA-related psychosis, which 
may mimic schizophrenia. Clinical symptoms of 
MA-induced psychosis include paranoia, 
delusions, and hallucinations.31,32 Psychosis occurs 
at least intermittently in a significant proportion 
of MA users, with wide variation in the severity 
and clinical course of symptoms.31  
Although the majority of MA-related 
psychiatric symptoms typically remit within a 
week of abstinence,23 a subset of MA users 
experience prolonged psychiatric 
symptomatology, even in the absence of a prior 
reported history of mental illness.33,34 Although 
MA is one of the most famous drugs in a drug-
induced psychosis, but recent studies finding 
suggest that designer drugs may have severe side-
effects in this domain than MA.35 
Medical considerations 
Chronic use of MA results in a variety of medical 
consequences, including cardiovascular disease, 
pulmonary problems, neurological problems, and 
dental disease. Long-term MA use is associated 
with elevated rates of infectious diseases, 
including HIV, hepatitis B and C, and 
endocarditis.29 Factors mediating the relationship 
between MA use and infectious diseases include 
increased risky sexual behaviors occurring in the 
context of MA intoxication, as well as injection 
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drug use and associated risk behaviors (e.g., 
needle sharing).36 
Clinical considerations 
The groups disproportionately impacted by MA 
have been women and men who have sex with 
men (MSM). Unlike with cocaine and heroin, 
where a very high proportion of users are male, 
women use MA at rates almost equal to men. 
Surveys among women suggest that they are 
more likely than men to be attracted to MA for 
weight loss and to control symptoms of 
depression. Over 70% of MA-dependent women 
report histories of physical and sexual abuse and 
are more likely than men to present for treatment 
with greater psychological distress. MA has been 
a popular drug among MSM since the 1980s. 
MSM report using MA to combat feelings of 
loneliness and isolation and to promote sexual 
desire and sexual behavior.37,38 In addition to the 
appeal of its sexual effects, MA serves as a coping 
tool for many MSM with HIV or AIDS. MSM with 
HIV report using MA to manage symptoms of 
HIV disease, such as fatigue, or to remedy  
HIV-related “burn out” and depression.37 
MA’s dramatic effect on sexual desire and 
sexual behavior has been a major public health 
concern, as it has been associated with increasing 
risk for transmission of HIV.37,39 Sexual practices 
associated with MA use include increased 
numbers of casual and anonymous sexual 
partners, increased anal intercourse, decreased 
condom use, sex trading, group sex, and more 
frequent and longer episodes of sexual 
activity.40–42 The multicenter AIDS cohort study 
and several other studies found a high correlation 
between MA use and HIV seroconversion40 and 
other sexually transmitted infections, such as 
syphilis, gonorrhea, and hepatitis.43–45 Treatment 
of MA dependence may be one of the most 
effective strategies in reducing the spread of HIV 
and other associated sexually transmitted 
infections. 
Pharmacotherapy treatments 
Until date, there is limited literature on  
evidence-based pharmacological treatment 
approaches for MA withdrawal. Antidepressants 
and anxiolytics may be used to ameliorate 
depressive and anxiety symptoms, though 
research suggests only limited benefits of 
antidepressants in reducing withdrawal 
symptoms.46 Neuroleptics may be used to treat 
MA-induced psychotic symptoms in the context 
of intoxication or recent use,47 and a recent study 
demonstrated the equivalent efficacy of 
Olanzapine (Zyprexa), an atypical neuroleptic, 
and haloperidol (Haldol), atypical neuroleptic, in 
improving psychotic symptoms related to 
amphetamine use.48 
The research literature lacks substantiation of 
efficacy of any medication as a treatment for MA 
dependence. Past work has failed to determine 
the efficacy of compounds such as selegiline 
(Eldepryl), sertraline (Zoloft), gabapentin 
(Neurontin), rivastigmine (Exelon), risperidone 
(Risperdal), ondansetron (Zofran),49 and Abilify 
(Aripiprazole)50 as potential treatments for MA 
dependence. 
Medication development for MA addiction 
generally strives to address deficits caused by MA 
use or associated with withdrawal. The target of 
therapeutic development has focused on initiation 
of abstinence and prevention of relapse. 
Bupropion (Wellbutrin), modafinil (Provigil), 
naltrexone, mirtazapine (Remeron), and baclofen 
(Lioresal) have exhibited limited utility in treating 
MA addiction, especially in conjunction with 
behavioral therapy. Other medications  
(e.g., lobeline, vigabatrin) are under 
consideration, but evidence for efficacy is lacking 
and the scant data that do exist contain no 
information regarding the suitability for various 
populations. Also of interest is a “replacement” or 
“substitution” approach with other stimulants 
such as methylphenidate,51,52 akin to methadone 
for opioid addiction. As with methadone, 
however, such a pharmacotherapy enables the 
patient to rehabilitate in other life areas, but does 
not lead to near-term abstinence from stimulants. 
There is at least one clinical trial in Iran, which 
recently compared aripiprazole with risperidone 
for treatment of MA induced psychosis, based on 
findings of this study risperidone is better choice 
for patients with positive psychosis symptoms 
and vice versa aripiprazole is better for patients 
with negative psychosis symptoms.53 
Matrix model of cognitive behavioral therapy 
(CBT): The matrix model incorporates principles of 
CBT in individual and group settings, family 
education, motivational interviewing, and 
behavioral therapy that employ CBT principles. 
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This manualized therapy has been proven effective 
in reducing MA use during the 16-week 
application of the intervention, in comparison to a 
“treatment as usual” condition.54–57 The matrix 
model has been evaluated as a stand-alone 
treatment for subgroups of MA abusers (e.g., gay 
and bisexual men and heterosexuals) and as the 
behavioral treatment platform in pharmacotherapy 
trials for MA dependence.57 
Contingency management (CM) therapy for 
treatment of stimulant use disorders employs 
principles of reinforcement for demonstration of 
desired behaviors. Drug use can be brought under 
control if desired behaviors that replace or 
compete with drug use are followed by rewards 
to increase the frequency of these behaviors. Thus, 
CM combined with a pharmacotherapy, such as 
modafinil that potentially enhances cognition or 
restores memory/learning processes impacted by 
MA dependence could be a potent approach. CM 
and CBT have been assessed for comparative 
effectiveness in treating stimulant dependence 
with a group of cocaine- and MA-dependent 
individuals-participants who received CM were 
retained in treatment significantly longer than 
those who received only CBT and they provided 
more stimulant-negative urine samples.55 
Another approach is empowering patients and 
their families by empower based interventions 
which could be effective for Iranian patients.56 
Harm reduction 
Some MA users who do not want treatment and 
cannot stop using MA should be considered as a 
target group of harm reduction services.58 Harms 
of MA use includes:  
• Direct medical harms such as cardiovascular 
disease, pulmonary problems, liver disease, 
strokes, pregnancy complications, 
neurological/mental complications, and dental 
complications. 
• Indirect medical harms such as HIV and 
hepatitis B and/or C because increase in high risk 
sex behaviors and sharing behaviors.59–62 Even in 
non-injecting MA users we can see an increase in 
the rate of hepatitis C because of pipe sharing.63 
• Indirect social harms such as increase in 
minor and major crimes64,65 and violence.66,67 
Current harm reduction strategies have been 
established in the context of heroin injecting drug 
users (IDUs) and have been shown to be effective 
for controlling HIV epidemic among these opiate 
using IDUs.68 Many of the harm reduction 
strategies developed for IDUs are likely to be 
useful for injecting MA users. Needle exchange 
has been shown to be an effective harm reduction 
strategy with opiate injectors, but there is 
evidence that MA injectors prefer to take, but 
avoid engagement with service providers 
resulting in less opportunity for patient 
education.69 Establishment of harm reduction 
facilities that are accepting, non-stigmatizing and 
provide food, and support services could be 
useful for engaging MA users into a safe 
environment. Furthermore, there is some 
evidence that the availability of smoking 
equipment such as pipes may provide some 
benefit in reducing injection use.  
MA use increases sexual risk behaviors61 
Condom promotion programs as well as safer sex 
education and safer sex negotiation for both male 
and female MA users can be part of harm 
reduction activities for MA users. In countries 
such as Iran that already have established harm 
reduction strategies for IDUs, MA harm reduction 
activities should be integrated with current 
activities to expand the impact of the programs. 
Consideration should be given to employing 
communication tools including mobile phones, 
virtual social networks, and text messaging to 
expand outreach activities.70–72 
Conclusion 
MA, a drug that is widely used in many parts of 
the world, produces significant acute and 
chronic medical and psychiatric conditions. 
Currently, there are no medications that have 
shown evidence of efficacy in the treatment of 
MA dependence. Several behavioral treatments 
have been shown to reduce MA use, but 
additional treatments are needed to provide a 
sufficient set of clinical tools to adequately treat 
the majority of MA-dependent individuals. The 
development of effective treatments that can 
reduce the use of MA as well as its consequent 
medical and psychiatric comorbidities is an 
important priority for future research. 
Integration of MA harm reduction strategies in 
current harm reduction programs as well as 
tailoring new innovative methods for better 
access to harm reduction assistance for both 
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injecting and non-injecting MA users should be 
considered as a priority. Iran and many other 
developing countries in the region are newly 
facing problems with MA, rapidly and widely, it 
is highly recommended that responsible 
authorities and scientific communities try to 
establish appropriate and effective response for 
prevention, treatment and harm reduction 
services, which specially should be tailored 
considering local resources and characteristics. 
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  ﭼﻜﻴﺪه
ﺑﺎﺷﺪ و در اﻳﺮان ﻧﻴﺰ ﻧﺰدﻳﻚ  ده ﻣﻲﮔﺮداﻧﻲ اﺳﺖ ﻛﻪ در دﻧﻴﺎ ﺑﻪ ﮔﺴﺘﺮدﮔﻲ در ﺣﺎل اﺳﺘﻔﺎ ﻣﺘﺎﻣﻔﺘﺎﻣﻴﻦ )ﺑﺎ ﻧﺎم ﻣﺼﻄﻠﺢ ﺷﻴﺸﻪ در اﻳﺮان( ﻣﺎده روان ﻣﻘﺪﻣﻪ:
ﺑﻪ ﻳﻚ دﻫﻪ اﺳﺖ ﻛﻪ در دﺳﺘﺮس ﻋﻤﻮم ﻣﺼﺮف ﻛﻨﻨﺪﮔﺎن ﻗﺮار ﮔﺮﻓﺘﻪ اﺳﺖ و ﺷﻴﻮع ﻣﺼﺮف ﺑﺴﻴﺎر ﺑﺎﻻﻳﻲ دارد. ﺑﻪ ﻫﻤﻴﻦ دﻟﻴﻞ ﺷﻨﺎﺧﺖ ﺑﻴﺸﺘﺮ آن 
  .ﺑﺎﺷﺪ ﻣﻮردﻧﻴﺎز درﻣﺎﻧﮕﺮان و ﭘﮋوﻫﺸﮕﺮان اﻳﻦ ﺣﻴﻄﻪ ﻣﻲ
ﻫﺎي ﻃﻮﻻﻧﻲ  ﻛﻪ ﺑﻌﻀﻲ ﻗﺎﺑﻞ ﺑﺮﮔﺸﺖ و ﺑﻌﻀﻲ ﺑﺮاي ﻣﺪت ﮔﺬارد ﺟﺎي ﻣﻲﻣﺼﺮف ﻣﺘﺎﻣﻔﺘﺎﻣﻴﻦ ﻋﻮارض ﻣﺘﻌﺪدي ﺑﺮ ﺳﻴﺴﺘﻢ ﻋﺼﺒﻲ ﻣﺮﻛﺰي ﺑﻪ  ﺑﺤﺚ:
آورد ﻛﻪ وي را ﺑﻪ ﺷﺪت ﺑﻪ  ﺑﺎﺷﺪ. اﻳﻦ ﻣﺎده ﺑﺎ ﺗﻮاﻧﺎﻳﻲ ﺗﺤﺮﻳﻚ ﻣﺪار ﭘﺎداش ﻣﻐﺰي، ﺗﺠﺮﺑﻴﺎﺗﻲ ﺑﺮاي ﻓﺮد ﻣﺼﺮف ﻛﻨﻨﺪه ﺑﻪ وﺟﻮد ﻣﻲ ﮔﻴﺮ ﻓﺮد ﻣﻲ ﮔﺮﻳﺒﺎن
و واﺑﺴﺘﮕﻲ ﺧﺘﻢ ﮔﺮدد. ﺷﻴﻮه ﻣﺼﺮف ﺗﺪﺧﻴﻨﻲ ﻳﺎ ﺗﺰرﻳﻘﻲ اﻳﻦ ﻣﺎده ﺑﺎﻋﺚ  ﺗﻮاﻧﺪ ﺑﻪ اﻋﺘﻴﺎد ﻛﻨﺪ و در ﻧﻬﺎﻳﺖ اﻳﻦ ﻓﺮاﻳﻨﺪ ﻣﻲ ﻣﺼﺮف ﻣﻜﺮر آن ﺗﺮﻏﻴﺐ ﻣﻲ
ﺷﻮد ﺗﺎ ﺗﺄﺛﻴﺮات آن ﺑﻼﻓﺎﺻﻠﻪ ﺑﻌﺪ از ﻣﺼﺮف در ﻓﺮد ﻣﺼﺮف ﻛﻨﻨﺪه ﺣﺲ ﺷﻮد و اﻳﻦ اﻣﺮ ﺑﺎﻋﺚ اﻓﺰاﻳﺶ اﺣﺘﻤﺎل اﻋﺘﻴﺎدآوري آن و ﻋﻮارض ﺟﺴﻤﻲ و  ﻣﻲ
ﻫﺎي  اﮔﺮﭼﻪ در اﻳﻦ ﺣﻴﻄﻪ ﭘﮋوﻫﺶ .ﻣﺘﺎﻣﻔﺘﺎﻣﻴﻦ در دﺳﺘﺮس ﻧﻴﺴﺖﮔﺮدد. ﺗﺎﻛﻨﻮن درﻣﺎن داروﻳﻲ ﻣﺆﺛﺮي ﺑﺮاي واﺑﺴﺘﮕﻲ ﺑﻪ  ﭘﺰﺷﻜﻲ ﺑﻴﺸﺘﺮي ﻣﻲ روان
ﻫﺎي  اﻧﺪ، اﻣﺎ ﻧﻴﺎز ﺑﻪ درﻣﺎن ﺑﺎﺷﺪ. ﭼﻨﺪﻳﻦ ﻣﺪل درﻣﺎن رﻓﺘﺎري ﺗﺄﺛﻴﺮ ﺧﻮد را در ﻛﺎﻫﺶ ﻣﻴﺰان ﻣﺼﺮف ﻣﺘﺎﻣﻔﺘﺎﻣﻴﻦ ﻧﺸﺎن داده اي در ﺟﺮﻳﺎن ﻣﻲ ﮔﺴﺘﺮده
 .ﮔﺮدد ﺑﻬﺘﺮي در اﻳﻦ زﻣﻴﻨﻪ اﺣﺴﺎس ﻣﻲ
ﺑﺮاي ﻣﺼﺮف ﻛﻨﻨﺪﮔﺎﻧﻲ ﻛﻪ ﺑﻪ دﻧﺒﺎل ﻗﻄﻊ ﻣﺼﺮف ﻣﺘﺎﻣﻔﺘﺎﻣﻴﻦ ﻧﻴﺴﺘﻨﺪ ﻣﺪﻧﻈﺮ ﻗﺮار ﮔﻴﺮد ﺗﺎ اﺣﺘﻤﺎل ﺑﺮوز ﺑﺎﻳﺪ راﻫﺒﺮدﻫﺎي ﻛﺎﻫﺶ آﺳﻴﺐ  ﮔﻴﺮي: ﻧﺘﻴﺠﻪ
ﻫﺎي ﺟﺴﻤﻲ در اﻳﻦ ﮔﺮوه ﻛﺎﻫﺶ ﻳﺎﺑﺪ. داﻣﻨﻪ ﭘﮋوﻫﺶ در اﻳﻦ ﺣﻴﻄﻪ ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﻧﻴﺎز ﺑﻪ  ( و دﻳﮕﺮ آﺳﻴﺐsuriv ycneicifedonummi namuH) VIH
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